Chronic obstructive pulmonary disease (COPD) is one of the most prevalent diseases of the respiratory system in the elderly, and it poses a grave threat to the survival and quality of life. Examining the pathogenesis of COPD is extremely important for COPD prevention and treatment. To date, however, there is no medication for chronic obstructive pulmonary disease that can delay the lung function decline over time. According to studies, vitamin D offers new hope for the treatment of COPD. A deficiency in vitamin D can exacerbate the progression of COPD, whereas adequate vitamin D has a therapeutic effect on COPD. This paper summarizes the relevant domestic and international research, discusses the possible mechanism of vitamin D's effect on COPD, and investigates the role of vitamin D, particularly in COPD patients.

Keywords: Vitamin D; Obstructive Pulmonary Disease; Chronicity; Pulmonary Function

Science Insights, 2022 October 31; Vol. 41, No. 5, pp.687-690.

In chronic obstructive pulmonary disease (COPD), aberrant airway inflammation brought on by hazardous gases or particles is linked to airflow limitation that is not entirely reversible (1). Patients may experience respiratory failure, pulmonary encephalopathy, and even death in severe cases during the acute aggravation of the illness, which poses a substantial threat to the patient’s quality of life (2). By 2030, according to some academics, COPD will be one of the top five chronic diseases worldwide in terms of morbidity and mortality (3). The significance of vitamin D and its active form, 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), in respiratory immune defense has come to light in recent years (4), and the percentage of COPD patients who are vitamin D deficient has increased from 31% and 77% (5). In order to support the prevention and treatment of COPD, we herein evaluated the connection between vitamin D and COPD and its impact on the disease’s development.

The Relationship between Vitamin D Deficiency and COPD
Peripheral blood serum 1,25-(OH)2D3 levels are less than 20 ng/mL, and then vitamin D deficiency should be diagnosed, according to the clinical practice guidelines for the assessment, treatment, and prevention of vitamin D deficiency (6). Vitamin D deficiency is prevalent in COPD patients, according to a study comprising 12,041 COPD patients, and it may be brought on by a systemic inflammatory response, hormone use, nutritional inadequacies, smoking-induced skin aging, and a lower capacity
to synthesis vitamin D (7). Patients with COPD may be deficient in vitamin D because of inadequate sun exposure and other variables that influence vitamin D absorption, production, storage, and metabolism (8). In addition, COPD patients frequently have impaired renal function and decreased adipose tissue as a result of intake, which impairs the skin’s capacity to produce vitamin D and results in vitamin D deficiency (9). In patients with COPD grades I–III, Yumrutepe et al. investigated the relationship between vitamin D and lung function, muscle strength, and balance (10), and the findings demonstrated that when COPD grades increased, the body’s vitamin D level declined in patients, resulting in a decline in pulmonary function, muscle strength, and balance. Balance and muscular strength are both compromised. Furthermore, vitamin D insufficiency is also prevalent in COPD patients, and the severity of the condition is correlated with the severity of the illness (FEV1 decrease) (11).

**Vitamin D-Binding Protein (VDBP) Gene Polymorphisms and COPD**

VDBP is a hepatocyte-secreted protein. It has the ability to bind vitamin D and G-actin, boost the chemotactic activity of C5 polypeptide on inflammatory cells such as neutrophils, and stimulate macrophages to remove extracellular G-actin from necrotic tissue (12). Results indicated that the genotype of VDBP may be associated with race. The GC1F genotype is the most prevalent in the Asian population, accounting for approximately 50% of the overall population (13), whereas the GC1S genotype is the most prevalent in the Caucasian population (14). Homozygous GC1F may be a high-risk factor for COPD, whereas allele 2 (GC2) may be a protective factor that reduces the incidence of COPD (15). GC gene polymorphism is associated with the content and function of vitamin D-binding protein, including the affinity of vitamin D-binding protein to 1,25-(OH)2D3, the rate of conversion into macrophage activating factor and levels, and the ability to promote neutrophil chemotaxis (12, 16). By influencing vitamin D level and function, GC gene polymorphism may influence the prevalence and progression of COPD.

**Vitamin D and Lung Function**

The most reliable data on the connection between vitamin D and lung function can be found in the third National Health and Nutrition Examination Survey conducted in the United States (17). In 14,091 patients, 1,25-(OH)2D3 concentrations ranged from the greatest (> 85.7 nmol/L) to the lowest (40.4 nmol/L). The difference in mean vital capacity (FVC) was 172 mL, while the mean difference in forced expiratory volume per second (FEV1) was 126 mL. The individuals received vitamin D supplements, milk, and plasma antioxidant levels. In the greatest and lowest 1,25-(OH)2D3 groups, the mean difference in FEV1 was 106 mL, while the mean difference in FVC was 142 mL. The researchers further altered the parameters of physical activity and showed the connection between vitamin D and lung health. After adjusting for variables like age, sex, body mass, and season, the two-year Korean Health and Nutrition Survey in South Korea revealed that the mean difference in FEV1 between the highest and lowest 1,25-(OH)2D3 was 51 mL, the mean difference in FVC was 38 mL, and the mean difference in FEV1 in patients with a history of pulmonary tuberculosis was as high as 229 mL (18). Additionally, the findings thoroughly supported the link between vitamin D status and lung health, particularly in tuberculosis patients. Furthermore, vitamin D deficiency worsens COPD symptoms in patients, which is directly associated to skeletal muscle weakness and an increased risk of fractures from osteoporosis (19, 20). Kyphosis, vertebral body, and rib fractures are all brought on by osteoporosis. The decrease in respiratory dynamism causes insufficient pulmonary ventilation and sputum obstruction, which exacerbates the disease, deteriorates lung function, and influences the occurrence and development of COPD. On the one hand, it can restrict respiratory movement and respiratory muscle dysfunction, resulting in a decrease in FEV1 and FVC. In a study of Canadian adults, a strong correlation was found between vitamin D insufficiency and lung function in overweight individuals, but not in normal-weight individuals (21).

**Vitamin D and Immune Regulation**

Recent study has demonstrated an imbalance between Th1 and Th2 cells in the T lymphocytes invading COPD. Th17 is a subpopulation of T cells that is significant in autoimmune illnesses like rheumatoid arthritis and psoriasis as well as chronic inflammatory cells (22). The main function of Th17 cells is interleukin (IL)-17 secretion. Accordingly, 1,25-(OH)2D3 can effectively prevent Th17 cells from secreting IL-17 (23). In stable COPD patients, IL-17 was expressed in the bronchial mucosa at a higher level than in the control group, and Th17 was crucial to the emergence and progression of chronic inflammation in COPD (24). 1,25-(OH)2D3 can greatly reduce Th17 generation, which is advantageous for disorders caused by T cell-mediated immunity (25). These investigations demonstrated that 1,25-(OH)2D3 can block the development and occurrence of illnesses that are mediated by Th1/Th17 cells. Vitamin D is advantageous in inflammatory bowel disease, multiple sclerosis, and other disorders because it can reduce the release of IL-17 and IFN- by increasing IL-4 and IL-10 (26). IL-10 possesses anti-inflammatory properties and can inhibit both the Th1 and Th2 immune responses as well as the generation and release of nearly all inflammatory mediators and cytokines (27).

**The Relationship between Vitamin D and Acute Exacerbations of COPD**

Acute COPD exacerbations (AECOPD) are most frequently brought on by bacterial, viral, or a combination of the two (28). Patients with vitamin D deficiency have reduced hCAP-18 antimicrobial peptide expression and impaired function of these cells, which increases their risk of developing or exacerbating respiratory tract infections (29). Increasing the concentration of 1,25-(OH)2D3 in patients with COPD to an ideal value can reduce the bacterial load and help prevent the disease (30). Insufficient vitamin D has been linked to chronic respiratory tract infections and bacterial colonization of the airways and the progression of COPD is slowed down and made worse by complications (31). In 973 COPD patients, Kunisaki et al. did not find a connection between the serum vitamin D level and the risk of an acute aggravation of the disease (32). However, Ginde and coworkers in their extensive cross-sectional investigation found
that serum vitamin D levels were strongly correlated with the exacerbation of COPD infection and inversely correlated with the prevalence of upper respiratory tract infections (33). Acute COPD exacerbations are more common in the winter, which may be associated to a lack of vitamin D (32, 34). Lack of vitamin D impairs immune cell function by weakening the expression of the antimicrobial peptide hCAP-18, which increases the risk of lower respiratory tract infections (35, 36).

**Conclusion**

In conclusion, people with COPD frequently lack vitamin D. AECOPD is closely associated to vitamin D insufficiency, which also has a significant role in the inflammation, immunological control, regulation of lung function, and occurrence and progression of COPD. In order to enhance the health and prognosis of COPD patients, it is advised that they take the proper amount of vitamin D supplements.

---

**References**

1. Murârescu ED, Mitrofan EC, Mihailovici MS. Chronic obstructive pulmonary disease in a new concept. Rom J Morphol Embryol 2007; 48(3):207-214.
2. Budweiser S, Jörres RA, Pfeifer M. Treatment of respiratory failure in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3(4):605-618. DOI: https://doi.org/10.2147/copd.s3814
3. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom 2018; 3:e4. DOI: https://doi.org/10.1017/gheg.2018.1
4. L Bishop E, Ismailova A, Dimeloe S, Hewison M, White JH. Vitamin D and immune regulation: Anti-bacterial, antiviral, anti-inflammatory. JBMR Plus 2020; 5(1):e10405. DOI: https://doi.org/10.1002/jbm4.10405
5. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, Coolen J, Mathieu C, Decramer M, Lambrechts D. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010; 65(3):215-220. DOI: https://doi.org/10.1136/thx.2009.120659
6. Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: When to test and how to treat. Mayo Clin Proc 2010; 85(8):752-757; quiz 757-758. DOI: https://doi.org/10.4065/mcp.2010.0138
7. Skaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Fenger RV, Linneberg A. Vitamin D status and chronic obstructive pulmonary disease: A prospective general population study. PLoS One 2014; 9(3):e90654. DOI: https://doi.org/10.1371/journal.pone.0090654
8. Janssens W, Lehouck A, Decramer M, Gayan-Ramirez G. Vitamin D and chronic obstructive pulmonary disease. Vitamin D and the Lung 2012; 3:239-260. DOI: https://doi.org/10.1007/978-1-61779-888-7_11
9. AbdelHalim HA, AboElNaga HH. Is renal impairment an anticipated COPD comorbidity? Respir Care 2016; 61(9):1201-1206. DOI: https://doi.org/10.4187/respcare.04516
10. Yumrutepe T, Aytemur ZA, Baysal O, Taskapan H, Taskapan CM, Hacielyayigil SS. Relationship between vitamin D and lung function, physical performance and balance on patients with stage I-III chronic obstructive pulmonary disease. Rev Assoc Med Bras (1992) 2015; 61(2):132-138. DOI: https://doi.org/10.1590/1806-9282.61.02.132
11. Baneen U, Naseem S. Correlation of severity of chronic obstructive pulmonary disease with serum vitamin-D level. J Family Med Prim Care 2018; 7(8):2268-2277. DOI: https://doi.org/10.4103/jfmpc.jfmpc_404_19
12. Bouillon R, Schuit F, Antonio L, Rastinejad F. Vitamin D binding protein: A historic overview. Front Endocrinol (Lausanne) 2020; 10:910. DOI: https://doi.org/10.3389/fendo.2019.00910
13. Chen H, Zhang L, He Z, Zhong X, Zhang J, Li M, Bai J. Vitamin D binding protein gene polymorphisms and chronic obstructive pulmonary disease: A meta-analysis. J Thorac Dis 2015; 7(8):1423-1440. DOI: https://doi.org/10.3978/j.issn.2072-1439.2015.08.16
14. Malik S, Fu L, Juras DJ, Karmali M, Wong BY, Godzdik A, Cole DE. Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit Rev Clin Lab Sci 2013; 50(1):1-22. DOI: https://doi.org/10.3109/10408363.2012.750262
15. Yuan C, Chang D, Lu G, Deng X. Genetic polymorphism and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2017; 12:1385-1393. DOI: https://doi.org/10.2147/COPD.S134161
16. Chun RF, Shieh A, Gottlieb C, Yecoubian V, Wang J, Hewison M, Adams JS. Vitamin D binding protein and the biological activity of vitamin D. Front Endocrinol (Lausanne) 2019; 10:718. DOI: https://doi.org/10.3389/fendo.2019.00718
17. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest 2005; 128(6):3792-3798. DOI: https://doi.org/10.1378/chest.128.6.3792
18. Kim MS, Choi CJ, Kwon KM, Kim KS, Choi WS, Oh YJ. Association of lung function with serum
25-hydroxyvitamin D level according to the presence of past pulmonary tuberculosis in Korean adults. Korean J Fam Med 2019; 40(2):93-99. DOI: https://doi.org/10.4016/kjfmm.17.0083

19. Sarkar M, Bhardwaj R, Madabhavi I, Khatana J. Osteoporosis in chronic obstructive pulmonary disease. Clin Med Insights Circ Respir Pulm Med 2015; 9:5-21. DOI: https://doi.org/10.4137/CCRPM.S22803

20. Cilen N, Maes K, Gayan-Ramirez G. Musculoskeletal disorders in chronic obstructive pulmonary disease. Biomed Res Int 2014; 2014:965764. DOI: https://doi.org/10.1155/2014/965764

21. Khan S, Mai XM, Chen Y. Plasma 25-hydroxyvitamin D associated with pulmonary function in Canadian adults with excess adiposity. Am J Clin Nutr 2013; 98(1):174-179. DOI: https://doi.org/10.3945/ajcn.112.054734

22. Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun 2018; 87:1-15. DOI: https://doi.org/10.1016/j.jaut.2017.12.007

23. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, Ichiyama K, Yoshimura A, Steinman L, Christakos S, Youssef S. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011; 31(17):3653-3669. DOI: https://doi.org/10.1128/MCB.05020-11

24. Ritzmann F, Lunding LP, Bals R, Wegmann M, Beisswenger C. IL-17 cytokines and chronic lung diseases. Cells 2022; 11(14):2132. DOI: https://doi.org/10.3390/cells11142132

25. Hafkamp FMJ, Taanman-Kueter EWM, van Capel TMM, Kormelink TG, de Jong EC. Vitamin D3 priming of dendritic cells shifts human neutrophil-dependent Th17 cell development to regulatory T cells. Front Immunol 2022; 13:872665. DOI: https://doi.org/10.3389/fimmu.2022.872665

26. Cantorna MT. Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch Biochem Biophys 2012; 523(1):103-106. DOI: https://doi.org/10.1016/j.abb.2011.11.001

27. León B, Ballesteros-Tato A. Modulating Th2 Cell Immunity for the Treatment of Asthma. Front Immunol 2021; 12:637948. DOI: https://doi.org/10.3389/fimmu.2021.637948

28. Shimizu K, Yoshii Y, Morozumi M, Chiba N, Ubukata K, Uruga H, Hanada S, Saito N, Kadota T, Ito S, Wakui H, Takasaka N, Minagawa S, Kojima J, Har a H, Numata T, Kawaishi M, Saito K, Araya J, Kaneko Y, Nakayama K, Kishi K, Kuwano K. Pathogens in COPD exacerbations identified by comprehensive real-time PCR plus older methods. Int J Chron Obstruct Pulm Dis 2015; 10:2009-2016. DOI: https://doi.org/10.2147/IJCPD.S82752

29. Vargas Buonfiglio LG, Cano M, Pezzulo AA, Vanegas Calderon OG, Zabner J, Gerke AK, Corellas AP. Effect of vitamin D3 on the antimicrobial activity of human airway surface liquid: Preliminary results of a randomised placebo-controlled double-blind trial. BMJ Open Respir Res 2017; 4(1):e000211. DOI: https://doi.org/10.1136/bmjresp-2017-000211

30. Herr C, Greulich T, Koczulla RA, Meyer S, Zakharkin T, Branscheidt M, Eschmann R, Bals R. The role of vitamin D in pulmonary disease: COPD, asthma, infection, and cancer. Respir Res 2011; 12(1):31. DOI: https://doi.org/10.1186/1465-9921-12-31

31. Chalmers JD, McHugh BJ, Docherty C, Govan JR, Hill AT. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013; 68(1):39-47. DOI: https://doi.org/10.1136/thoraxjnl-2012-202125

32. Kunisaki KM, Niewoehner DE, Connett JE; COPD Clinical Research Network. Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: A prospective cohort study. Am J Respir Crit Care Med 2012; 185(3):286-290. DOI: https://doi.org/10.1164/rccm.201109-1844OC

33. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169(4):384-390. DOI: https://doi.org/10.1001/archinternmed.2008.560

34. Malinovschi A, Masoero M, Belocchia M, Ciuffreda A, Solidoro P, Matti A, Mercante L, Heffler E, Rolla G, Bucca C. Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients. Respir Res 2014; 15(1):131. DOI: https://doi.org/10.1186/s12931-014-0131-0

35. Gombart AF. The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Future Microbiol 2009 Nov; 4(9):1151-1165. DOI: https://doi.org/10.2217/fmb.09.87

36. White JH. Emerging roles of vitamin D-induced antimicrobial peptides in antiviral innate immunity. Nutrients 2022; 14(2):284. DOI: https://doi.org/10.3390/nu14020284

Received: August 02, 2022 | Revised: August 17, 2022 | Accepted: August 28, 2022

https://bonoi.org/index.php/si

SI | October 31, 2022 | vol. 41 | no. 5 | 690